{"id":933619,"date":"2026-02-03T08:09:54","date_gmt":"2026-02-03T13:09:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/"},"modified":"2026-02-03T08:09:54","modified_gmt":"2026-02-03T13:09:54","slug":"in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/","title":{"rendered":"IN8bio to Present at Upcoming Investor and Scientific Conferences in February"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Feb.  03, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-ovnFuznlTSZqMVNuClqvdHMAplTmKnssdnPlOAG-_dJzhPUeNfqYvUBnNvGNTL86incmuJXE5oY2uR5-OfBhg==\" rel=\"nofollow\" target=\"_blank\">IN8bio, Inc<\/a>. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4 ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February.<\/p>\n<p>Conference participation details are as follows:<\/p>\n<p>\n        <strong>Noble Emerging Growth Virtual Equity Conference<\/strong><br \/>\n        <br \/>Date: Thursday, February 5, 2026<br \/>Time: 3:00 p.m. ET<br \/>Location: Virtual <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kKC0uEk98eLYKnVzq5ZkSUb5pbIFNfgorUQaQsPr6MYXWcHILPq1WEhhKiTDnpFtKXIaErrhgorqanLeFvdvGkBK-LPJaUkGFEDYntm5H19ahwbixMBWCLJGBQTH-mVIL4VEhcVZKdNuoJv_yPUOjLwicC6mOiwxltvktd8yP3-22rk56gcfg0jqcRrDBer0\" rel=\"nofollow\" target=\"_blank\">Investor Registration<\/a><\/p>\n<p>\n        <strong>IO360\u00b0 Conference<\/strong><br \/>\n        <br \/>Date: Thursday, February 12, 2026<br \/>Time: 1:20 p.m. \u2013 1:40 p.m. ET<br \/>Session: IO Clinical Advancements Plenary <br \/>Presentation title: IN8bio\u2019s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors &amp; Results from Phase 1\/2 Study in Newly Diagnosed GBM<\/p>\n<p>Additional details, including any available webcast information, will be posted on the Events &amp; Presentations section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yRg0SYct3q-P8fEkl4zWXt8WQytKVmCLJ4EtKA4HP-MkwaKBEUwsUioTkxT0NbEgiovjOgfZgk3QOxiJvTAgAQ==\" rel=\"nofollow\" target=\"_blank\">www.in8bio.com<\/a>.<\/p>\n<p>\n        <strong>About IN8bio<\/strong>\n      <\/p>\n<p>IN8bio is a clinical-stage biopharmaceutical company developing \u03b3\u03b4 T cell product candidates for unmet medical needs. \u03b3\u03b4 T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company&#8217;s lead program, INB-100, is focused on acute myeloid leukemia, evaluating haplo-matched allogeneic \u03b3\u03b4 T cells given to patients following a hematopoietic stem cell transplant. The Company is also evaluating autologous DeltEx DRI \u03b3\u03b4 T cells, in combination with standard of care, for glioblastoma in its INB-200 and 400 programs, and INB-600, advancing novel \u03b3\u03b4 T cell engagers for potential oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.<\/p>\n<p>\n        <strong>Investors &amp; Company Contacts:<\/strong>\n      <\/p>\n<p>IN8bio, Inc.<br \/>Patrick McCall<br \/>646.933.5603<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1JHjZUIS7CnAX5qRl0OpU_Mub78Dl1ivg7YPjBcPbFa7I6qSB2W5Gl43W5m42Czf0ip0eMxWzLtQy5WmjLfWezJso72Ov-PRMwQ078Mmi4g=\" rel=\"nofollow\" target=\"_blank\">pfmccall@IN8bio.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong>\n      <\/p>\n<p>Kimberly Ha<br \/>KKH Advisors<br \/>917.291.5744<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dct5FQlL-rtFRjxKNZZ2PU_k0DPVgHPvn2ftYsbx0cDeVxKKt3Hq25k2cDcGFBN7Hj7Rtv2OQonaIO8j9vRqZLm348aNu8r0g04GRo9SiTFsD0LSS4xRZXic3MkHBBt4\" rel=\"nofollow\" target=\"_blank\">kimberly.ha@kkhadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODA4NWNlYjQtNTFhNC00OTJlLWE1NmEtMDIwNGVhYWVkYmY0LTExMzQ1NzctMjAyNi0wMi0wMy1lbg==\/tiny\/IN8bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4 ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity Conference Date: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Investor Registration IO360\u00b0 Conference Date: Thursday, February 12, 2026Time: 1:20 p.m. \u2013 1:40 p.m. ETSession: IO Clinical Advancements Plenary Presentation title: IN8bio\u2019s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors &amp; Results from Phase 1\/2 Study in Newly Diagnosed GBM Additional details, including any available webcast information, will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IN8bio to Present at Upcoming Investor and Scientific Conferences in February&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933619","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IN8bio to Present at Upcoming Investor and Scientific Conferences in February - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IN8bio to Present at Upcoming Investor and Scientific Conferences in February - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4 ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity Conference Date: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Investor Registration IO360\u00b0 Conference Date: Thursday, February 12, 2026Time: 1:20 p.m. \u2013 1:40 p.m. ETSession: IO Clinical Advancements Plenary Presentation title: IN8bio\u2019s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors &amp; Results from Phase 1\/2 Study in Newly Diagnosed GBM Additional details, including any available webcast information, will be &hellip; Continue reading &quot;IN8bio to Present at Upcoming Investor and Scientific Conferences in February&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T13:09:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IN8bio to Present at Upcoming Investor and Scientific Conferences in February\",\"datePublished\":\"2026-02-03T13:09:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/\"},\"wordCount\":280,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/\",\"name\":\"IN8bio to Present at Upcoming Investor and Scientific Conferences in February - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=\",\"datePublished\":\"2026-02-03T13:09:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IN8bio to Present at Upcoming Investor and Scientific Conferences in February\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IN8bio to Present at Upcoming Investor and Scientific Conferences in February - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/","og_locale":"en_US","og_type":"article","og_title":"IN8bio to Present at Upcoming Investor and Scientific Conferences in February - Market Newsdesk","og_description":"NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) &#8212; IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (\u03b3\u03b4 ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting the following investor and scientific conferences in February. Conference participation details are as follows: Noble Emerging Growth Virtual Equity Conference Date: Thursday, February 5, 2026Time: 3:00 p.m. ETLocation: Virtual Investor Registration IO360\u00b0 Conference Date: Thursday, February 12, 2026Time: 1:20 p.m. \u2013 1:40 p.m. ETSession: IO Clinical Advancements Plenary Presentation title: IN8bio\u2019s Unique DeltEx Drug Resistant Immunotherapy (DRI) Approach to Solid Tumors &amp; Results from Phase 1\/2 Study in Newly Diagnosed GBM Additional details, including any available webcast information, will be &hellip; Continue reading \"IN8bio to Present at Upcoming Investor and Scientific Conferences in February\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-03T13:09:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IN8bio to Present at Upcoming Investor and Scientific Conferences in February","datePublished":"2026-02-03T13:09:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/"},"wordCount":280,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/","name":"IN8bio to Present at Upcoming Investor and Scientific Conferences in February - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=","datePublished":"2026-02-03T13:09:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzI1OSM3NDA0ODcxIzIxMjMwMDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/in8bio-to-present-at-upcoming-investor-and-scientific-conferences-in-february\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IN8bio to Present at Upcoming Investor and Scientific Conferences in February"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933619"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}